Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Joline S.W. Lind"'
Autor:
Joline S.W. Lind, Egbert F. Smit
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
A therapeutic plateau seems to have been reached with the standard treatment of cytotoxic chemotherapy alone for advanced stage non-small cell lung cancer (NSCLC) and new treatment options are urgently needed. Recent insight into the molecular biolog
Externí odkaz:
https://doaj.org/article/6b6734c616404170a1635ab3e4845869
Autor:
Hendricus Groen, Julia Grigorieva, Anne-Marie C. Dingemans, Egbert F. Smit, J. Roder, Joline S.W. Lind, H. Roder, Justine L. Kuiper
Publikováno v:
British Jounal of Cancer, 107(11), 1820-1825. Nature Publishing Group
British Journal of Cancer, 107(11), 1820-1825. Nature Publishing Group
Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C & Smit, E F 2012, ' VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib ', British Journal of Cancer, vol. 107, no. 11, pp. 1820-1825 . https://doi.org/10.1038/bjc.2012.470
British Journal of Cancer
British Journal of Cancer, 107(11), 1820-1825. Nature Publishing Group
Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C & Smit, E F 2012, ' VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib ', British Journal of Cancer, vol. 107, no. 11, pp. 1820-1825 . https://doi.org/10.1038/bjc.2012.470
British Journal of Cancer
BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Autor:
Egbert F. Smit, Joline S.W. Lind, Thang V. Pham, Henk M.W. Verheul, Jaco C. Knol, Johannes Voortman, Connie R. Jimenez, Maria Rovithi
Publikováno v:
Rovithi, M, Lind, J S W, Pham, T V, Voortman, J, Knol, J C, Verheul, H M W, Smit, E F & Jimenez, C R 2016, ' Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer ', Proteomics. Clinical applications, vol. 10, no. 7, pp. 743-749 . https://doi.org/10.1002/prca.201600025
Proteomics. Clinical applications, 10(7), 743-749. Wiley-VCH Verlag
Proteomics. Clinical applications, 10(7), 743-749. Wiley-VCH Verlag
Purpose We validated a previously reported proteomic signature, associated with treatment outcome, in an independent cohort of patients with non-small cell lung cancer (NSCLC). A novel peptide signature was developed to predict toxicity. Experimental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d800222b6ff43386def585c9893fe13
https://research.vumc.nl/en/publications/c4181802-411f-46d1-bf5b-9bceeae4ec58
https://research.vumc.nl/en/publications/c4181802-411f-46d1-bf5b-9bceeae4ec58
Autor:
Egbert F. Smit, Joline S.W. Lind, Martijn R. Meijerink, Michel Öllers, Cornelis van Kuijk, Pieter E. Postmus, Dirk De Ruysscher, Anne-Marie C. Dingemans
Publikováno v:
European Radiology, 20(12), 2890-2898. Springer Verlag
Lind, J S W, Meijerink, M R, Dingemans, A M C, van Kuijk, C, Ollers, M C, De Ruysscher, D, Postmus, P E & Smit, E F 2010, ' Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? ', European Radiology, vol. 20, no. 12, pp. 2890-2898 . https://doi.org/10.1007/s00330-010-1869-5
European Radiology, 20(12), 2890-2898. Springer, Cham
European Radiology
Lind, J S W, Meijerink, M R, Dingemans, A M C, van Kuijk, C, Ollers, M C, De Ruysscher, D, Postmus, P E & Smit, E F 2010, ' Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? ', European Radiology, vol. 20, no. 12, pp. 2890-2898 . https://doi.org/10.1007/s00330-010-1869-5
European Radiology, 20(12), 2890-2898. Springer, Cham
European Radiology
Objective We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatme
Publikováno v:
Journal of Thoracic Oncology, 5(4), 554-557. International Association for the Study of Lung Cancer
Lind, J S W, Postmus, P E & Smit, E F 2010, ' Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer A Brief Report ', Journal of Thoracic Oncology, vol. 5, no. 4, pp. 554-557 . https://doi.org/10.1097/JTO.0b013e3181d3e47e
Lind, J S W, Postmus, P E & Smit, E F 2010, ' Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer A Brief Report ', Journal of Thoracic Oncology, vol. 5, no. 4, pp. 554-557 . https://doi.org/10.1097/JTO.0b013e3181d3e47e
Background The osteoblastic bone flare or response is the paradoxical phenomenon of increase in the quantity and/or density of bone lesions in the presence of well-documented disease response to treatment in other tumor sites. It results from the rap
Autor:
Egbert F. Smit, Henk M.W. Verheul, Elisa Giovannetti, Joline S.W. Lind, Richard J. Honeywell, Carmelo Tibaldi, K. Yarzadah, Nienke Losekoot, G.J. Peters, Maudy Walraven
Publikováno v:
Honeywell, R J, Yarzadah, K, Giovannetti, E, Losekoot, N, Smit, E F, Walraven, M, Lind, J S W, Tibaldi, C, Verheul, H M W & Peters, G J 2010, ' Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry ', Journal of Chromatography B, vol. 878, no. 15-16, pp. 1059-1068 . https://doi.org/10.1016/j.jchromb.2010.03.010
Journal of Chromatography B, 878(15-16), 1059-1068. Elsevier
Journal of Chromatography B, 878(15-16), 1059-1068. Elsevier
A fast, sensitive, universal and accurate method for the determination of four different tyrosine kinase inhibitors from biological material was developed using LC-MS/MS techniques. Utilizing a simple protein precipitation with acetonitrile a 20 micr
Publikováno v:
International journal of radiation oncology, biology, physics, 74(5), 1391-1396. Elsevier Inc.
Lind, J S W, Lagerwaard, F J, Smit, E F & Senan, S 2009, ' Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases from Non-Small-Cell Lung Cancer ', International journal of radiation oncology, biology, physics, vol. 74, no. 5, pp. 1391-1396 . https://doi.org/10.1016/j.ijrobp.2008.10.026
Lind, J S W, Lagerwaard, F J, Smit, E F & Senan, S 2009, ' Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases from Non-Small-Cell Lung Cancer ', International journal of radiation oncology, biology, physics, vol. 74, no. 5, pp. 1391-1396 . https://doi.org/10.1016/j.ijrobp.2008.10.026
Purpose Erlotinib has shown activity in patients with brain metastases from non–small-cell lung cancer. The present dose-escalation Phase I trial evaluated the toxicity of whole brain radiotherapy (WBRT) with concurrent and maintenance erlotinib in
Autor:
Egbert F. Smit, Elisa Giovannetti, Richard J. Honeywell, Mariette Labots, Elena Galvani, G.J. Peters, Joline S.W. Lind, Rocco Sciarrillo, Henk L. Dekker, Henk M.W. Verheul
Publikováno v:
Giovannetti, E, Labots, M, Dekker, H, Galvani, E, Lind, J S W, Sciarrillo, R, Honeywell, R, Smit, E F, Verheul, H M & Peters, G J 2013, ' Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells ', Current Pharmaceutical Design, vol. 19, no. 5, pp. 927-39 .
Giovannetti, E, Labots, M, Dekker, H, Galvani, E, Lind, J S W, Sciarrillo, R, Honeywell, R J, Smit, E F, Verheul, H M & Peters, G J 2013, ' Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells ', Current Pharmaceutical Design, vol. 19, no. 5, pp. 927-939 . https://doi.org/10.2174/138161213804547268
Current Pharmaceutical Design, 19(5), 927-939. Bentham Science Publishers B.V.
Current Pharmaceutical Design, 19(5), 927-39. Bentham Science Publishers B.V.
Scopus-Elsevier
Giovannetti, E, Labots, M, Dekker, H, Galvani, E, Lind, J S W, Sciarrillo, R, Honeywell, R J, Smit, E F, Verheul, H M & Peters, G J 2013, ' Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells ', Current Pharmaceutical Design, vol. 19, no. 5, pp. 927-939 . https://doi.org/10.2174/138161213804547268
Current Pharmaceutical Design, 19(5), 927-939. Bentham Science Publishers B.V.
Current Pharmaceutical Design, 19(5), 927-39. Bentham Science Publishers B.V.
Scopus-Elsevier
Combination of drugs with different targets is a logical approach to overcome multilevel cross-stimulation among key pathways in NSCLC progression such as EGFR, K-Ras and VEGFR. The sorafenib-erlotinib combination showed clinical activity and accepta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd5a7efd2759702d35c66da3b1fe849
https://research.vumc.nl/en/publications/84dfeeae-8c47-4ba3-a28c-6d82f36d9efd
https://research.vumc.nl/en/publications/84dfeeae-8c47-4ba3-a28c-6d82f36d9efd
Publikováno v:
Lind, J S W, Senan, S & Smit, E F 2012, ' Pulmonary Toxicity After Bevacizumab and Concurrent Thoracic Radiotherapy Observed in a Phase I Study for Inoperable Stage III Non-Small-Cell Lung Cancer ', Journal of Clinical Oncology, vol. 30, no. 8, pp. E104-E108 . https://doi.org/10.1200/JCO.2011.38.4552
Journal of Clinical Oncology, 30(8), E104-E108. American Society of Clinical Oncology
Journal of Clinical Oncology, 30(8), E104-E108. American Society of Clinical Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1ee30ef999acf542fa667a654f82c86
https://research.vumc.nl/en/publications/6939f587-29ac-449e-9856-8ed9938f9b57
https://research.vumc.nl/en/publications/6939f587-29ac-449e-9856-8ed9938f9b57
Autor:
Egbert F. Smit, Suresh Senan, Pieter E. Postmus, Joline S.W. Lind, Ben J. Slotman, Frank J. Lagerwaard
Publikováno v:
Lind, J S W, Lagerwaard, F J, Smit, E F, Postmus, P E, Slotman, B J & Senan, S 2011, ' Time for Reappraisal of Extracranial Treatment Options? Synchronous Brain Metastases From Nonsmall Cell Lung Cancer ', Cancer, vol. 117, no. 3, pp. 597-605 . https://doi.org/10.1002/cncr.25416
Cancer, 117(3), 597-605. John Wiley and Sons Inc.
Cancer, 117(3), 597-605. John Wiley and Sons Inc.
BACKGROUND. The optimal treatment of the primary tumor in patients with brain metastases (BM) from newly diagnosed nonsmall cell lung cancer (NSCLC) remains unclear. The authors aimed to identify patient groups with synchronous BM for whom radical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b486e171ce30a8232e72dc1daf325b6
https://research.vumc.nl/en/publications/9d927f40-43b2-46fa-8664-92629d83a1aa
https://research.vumc.nl/en/publications/9d927f40-43b2-46fa-8664-92629d83a1aa